Resolution Minerals Ltd (ASX:RML, OTCQB:RLMLF, FRA:NC3)'s CEO of US operations, Craig Lindsay, will present at the 38th Annual Roth Conference in Dana Point, California, as the company prepares for a planned NASDAQ listing.
The conference will take place from March 22 to 24, 2026, at the Ritz-Carlton Hotel in Dana Point, California, bringing together public and private growth companies with institutional investors for presentations, one-on-one meetings and industry panels focused on capital markets and growth sectors.
Sovereign Metals Ltd (ASX:SVM, OTCQX:SVMLF, AIM:SVML, FRA:SVM) has signed a memorandum of understanding (MoU) with Japanese trading and investment group Mitsui & Co. Ltd to supply natural rutile from its flagship Kasiya Rutile-Graphite Project in Malawi, marking another step towards commercialisation of the world-class deposit.
Under the non-binding agreement, the parties will work towards a formal offtake arrangement covering up to 70,000 tonnes per year of natural rutile concentrate from Kasiya, with an initial four-year supply period from first production and the potential for a further five-year extension.
Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has expanded the scale of mineralisation at its Little Gem prospect in Western Australia after new drilling extended the system and revealed a previously unrecognised parallel mineralised trend.
Latest exploration results have stretched the mineralised envelope at Little Gem to more than 1,500 metres of strike and 750 metres vertically below surface, with mineralisation still open in multiple directions as drilling continues.
Berkeley Energia Ltd (LSE:BKY, ASX:BKY) shares found support on Wednesday, rising 8.7% to 25p, as the company, which is locked in a legal dispute with Spain, released interim financial results that confirmed robust cash resources.
Cash reserves stood at A$68.4 million at period-end, down from A$73.6 million at 30 June, with no debt on the balance sheet.
Ariana Resources PLC (AIM:AAU, ASX:AA2, FRA:4A6) has told investors that drilling at its Dokwe North deposit in Zimbabwe has returned high-grade gold intercepts that strengthen the case for resource growth beyond the current model, including one of the best RC hits from its 2025-2026 programme.
The standout result was 4 metres at 16.90 grammes per tonne gold from 69 metres in hole DRC25, with other key intercepts including 10 metres at 7.67 g/t from 110 metres in DRC23 and 10 metres at 4.91 g/t from 156 metres in DRC22.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has launched a capital raising of up to $20 million through a combination of an institutional placement and a share purchase plan (SPP), with funds earmarked to support the continued clinical development of its azer-cel cancer therapy.
The clinical-stage immuno-oncology company has already secured firm commitments for $12 million in a strongly supported two-tranche placement to domestic and international institutional and sophisticated investors.
American Tungsten & Antimony Ltd (ASX:AT4, OTCQB:ATALF, FRA:4VZ) has reported a high-grade antimony discovery from its maiden drilling campaign at the Antimony Canyon Project in Utah, with early results confirming the presence of a significant mineralised system.
Initial diamond drilling at the Little Emma prospect returned multiple shallow, high-grade intersections, including 11.03 metres at 3.1% antimony from 25.91 metres, including 2.62 metres at 12.54%, and 8.47 metres at 2.67% antimony from 31.15 metres, including 2.2 metres at 9.69%. These intercepts represent more than 90% of true width and occur within a flat-lying mineralised horizon interpreted to host stibnite-rich hydrothermal breccias.
Novo Nordisk (NYSE:NVO) has drawn regulatory scrutiny in the US after the Food and Drug Administration (FDA) issued the pharmaceutical giant a warning letter over failures in how it handled reports of adverse drug events linked to several of its medicines — including semaglutide, the active ingredient behind blockbuster treatments such as Ozempic.
The March 5 letter follows an FDA inspection of Novo Nordisk’s US operations between January 13 and February 7, 2025. Investigators concluded the company did not comply with key pharmacovigilance requirements governing how drugmakers monitor and report safety events once medicines are on the market.
Oil prices have swung sharply this week as the near-closure of the Strait of Hormuz continues to send shockwaves through global energy markets, with the International Energy Agency now weighing an unprecedented drawdown of strategic reserves to stabilise supply.
Brent Crude retreated to around $88 per barrel on Wednesday, while West Texas Intermediate hovered near $83, after reports emerged that the Paris-based IEA is proposing a reserve release that would surpass the 182 million barrels deployed during the Russia-Ukraine war in 2022 — the largest coordinated intervention in the agency's history.
Lynas Rare Earths Ltd (ASX:LYC, OTC:LYSCF) surged at the open after extending its long-term supply agreement with Japan Australia Rare Earths (JARE) to 2038, securing offtake for key rare earth materials used in Japan.
Shares in the miner rose 11.5% in early trade, making Lynas the strongest performer on the S&P/ASX 200 and recouping losses from the past week following conflict in Iran.
DroneShield Ltd (ASX:DRO, OTC:DRSHF) has established counter-drone manufacturing in the European Union, expanding its industrial footprint in the region and increasing production capacity as demand for sovereign defence capability grows.
The move comes amid stronger momentum across Europe, where national military investment is rising under the ReArm Europe Plan/Readiness 2030 initiative, driving demand for mature, scalable counter-drone systems.
A new listed investment trust focused on global fixed income markets is preparing to join the ASX later this month, with the Kapstream Investment Trust (ASX:KIT) seeking to raise up to $300 million ahead of its expected listing on March 30.
The trust will offer investors exposure to a diversified portfolio of global credit securities, with a strategy centred on generating regular income through actively managed investments across investment-grade and other high-quality debt markets.
Patrys Ltd (ASX:PAB) has begun manufacturing and regulatory activities for RLS-2201, its proprietary injectable quetiapine formulation being developed to treat delirium, as it works toward launching a first-in-human Phase 0 clinical trial in the second half of 2026.
Engineering batch manufacturing had been initiated at BioCina, marking the first production run of the reformulated product under conditions designed to replicate commercial-scale processes. The batch is expected to support manufacturing process validation, stability testing and the production of early material for clinical trial activities.
MetalsGrove Mining Ltd (ASX:MGA) has identified a second gold exploration target at its Zuénoula permit in Côte d’Ivoire after district-scale soil sampling outlined a new anomalous zone known as the Fifty-Five Area.
The target sits about 1 kilometre north of the previously reported Central Area and is defined by four anomalous soil samples over a strike length of 2.4 kilometres.
Titan Minerals Ltd (ASX:TTM, OTC:TTTNF) has reported further wide zones of gold-silver ± copper mineralisation from drilling at the Kaliman target within its Dynasty Gold Project in southern Ecuador, reinforcing the potential scale of the deposit ahead of an updated Mineral Resource Estimate (MRE) expected later this quarter.
The company’s 2025 drilling campaign, which totalled around 25,000 metres, has continued to confirm extensive porphyry and breccia-hosted mineralisation across the project area. The latest results highlight strong continuity of mineralisation at Kaliman, which remains open both along strike and at depth.
Alchemy Resources Limited (ASX:ALY, FRA:45A) has agreed to sell its Karonie and Lake Rebecca gold projects in Western Australia to Forrestania Resources Ltd (ASX:FRS) in a deal valued at $5 million, to be settled in Forrestania shares.
Under the binding heads of agreement, Alchemy will receive 7,725,587 fully paid Forrestania shares, priced using Forrestania’s 10-day volume weighted average price of $0.6472 per share at the date of the agreement.